

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:08:06 ON 29 JUN 2006

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'PCTFULL' ENTERED AT 13:08:26 ON 29 JUN 2006

COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 27 JUN 2006 <20060627/UP>

MOST RECENT UPDATE WEEK: 200625 <200625/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE

(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,

PLEASE SEE HELP COST <<<

=> s MDH or (mitochondrial malate dehydrogenase)

789 MDH

9 MDHS

794 MDH

(MDH OR MDHS)

10031 MITOCHONDRIAL

1 MITOCHONDRIALS

10031 MITOCHONDRIAL

(MITOCHONDRIAL OR MITOCHONDRIALS)

6890 MALATE

368 MALATES

7208 MALATE

(MALATE OR MALATES)

19368 DEHYDROGENASE

1522 DEHYDROGENASES

19798 DEHYDROGENASE

(DEHYDROGENASE OR DEHYDROGENASES)

16 MITOCHONDRIAL MALATE DEHYDROGENASE

(MITOCHONDRIAL (W) MALATE (W) DEHYDROGENASE)

L1 807 MDH OR (MITOCHONDRIAL MALATE DEHYDROGENASE)

=> s (HIV-1 TAT) or (human deficiency virus TAT)

30850 HIV

93 HIVS

30855 HIV

(HIV OR HIVS)

1030175 1

19197 TAT

406 TATS

19520 TAT

(TAT OR TATS)

591 HIV-1 TAT

(HIV (W) 1 (W) TAT)

207671 HUMAN

81883 HUMANS
 216869 HUMAN
 (HUMAN OR HUMANS)
 28257 DEFICIENCY
 27613 DEFICIENCIES
 49637 DEFICIENCY
 (DEFICIENCY OR DEFICIENCIES)
 65233 VIRUS
 46247 VIRUSES
 74697 VIRUS
 (VIRUS OR VIRUSES)
 19197 TAT
 406 TATS
 19520 TAT
 (TAT OR TATS)
 3 HUMAN DEFICIENCY VIRUS TAT
 (HUMAN(W) DEFICIENCY(W) VIRUS(W) TAT)
 L2 594 (HIV-1 TAT) OR (HUMAN DEFICIENCY VIRUS TAT)

=> s l1 and l2

L3 15 L1 AND L2

=> s l3 not py>2002

414028 PY>2002

L4 6 L3 NOT PY>2002

=> d ibib 1-6

L4 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2001057277 PCTFULL ED 20020827
 TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN FETAL
 LIVER
 TITLE (FRENCH): SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE FOIE FOETAL HUMAIN
 INVENTOR(S): PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 PATENT ASSIGNEE(S): MOLECULAR DYNAMICS, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057277	A2	20010809

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

WO 2001-US669	A	20010130
US 2000-60/180,312		20000204
US 2000-60/207,456		20000526
US 2000-09/608,408		20000630
US 2000-09/632,366		20000803
US 2000-60/234,687		20000921

US 2000-60/236,359 20000927
GB 2000-0024263.6 20001004

L4 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2001057273 PCTFULL ED 20020827
TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN ADULT
LIVER
TITLE (FRENCH): SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
DANS LE FOIE ADULTE HUMAIN
INVENTOR(S): PENN, Sharron, G.;
HANZEL, David, K.;
CHEN, Wensheng;
RANK, David, R.
PATENT ASSIGNEE(S): AEOMICA, INC.;
PENN, Sharron, G.;
HANZEL, David, K.;
CHEN, Wensheng;
RANK, David, R.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001057273	A2	20010809

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

WO 2001-US664	A	20010130
US 2000-60/180,312		20000204
US 2000-60/207,456		20000526
US 2000-09/608,408		20000630
US 2000-09/632,366		20000803
US 2000-60/234,687		20000921
US 2000-60/236,359		20000927
GB 2000-0024263.6		20001004

L4 ANSWER 3 OF 6

ACCESSION NUMBER: 2000029421 PCTFULL ED 20020515
TITLE (ENGLISH): SELECTION SYSTEM FOR GENERATING EFFICIENT PACKAGING
CELLS FOR LENTIVIRAL VECTORS
TITLE (FRENCH): SYSTEME DE SELECTION POUR LA PRODUCTION DE CELLULES
D'ENCAPSIDATION EFFICACE POUR VECTEURS LENTIVIRAUX
INVENTOR(S): MCGUINNESS, Ryan;
NALDINI, Luigi
PATENT ASSIGNEE(S): CELL GENESYS, INC.;
MCGUINNESS, Ryan;
NALDINI, Luigi
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2000029421	A1	20000525

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA

UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US24018 A 19991112
PRIORITY INFO.: US 1998-60/108,169 19981113

L4 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999060012 PCTFULL ED 20020515
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF
OLIGONUCLEOTIDES
TITLE (FRENCH): COMPOSITIONS ET PROCEDES POUR L'ADMINISTRATION NON
PARENTERALE D'OLIGONUCLEOTIDES
INVENTOR(S): TENG, Ching-Leou;
COOK, Phillip, D.;
TILLMAN, Lloyd;
HARDEE, Gregory, E.;
ECKER, David, J.;
MANOHARAN, Muthiah
PATENT ASSIGNEE(S): ISIS PHARMACEUTICALS, INC.;
TENG, Ching-Leou;
COOK, Phillip, D.;
TILLMAN, Lloyd;
HARDEE, Gregory, E.;
ECKER, David, J.;
MANOHARAN, Muthiah
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9960012	A1	19991125

DESIGNATED STATES
W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG

APPLICATION INFO.: WO 1999-US11394 A 19990520
PRIORITY INFO.: US 1998-09/082,624 19980521

L4 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999011820 PCTFULL ED 20020515
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND
QUANTITATION OF DELETION SEQUENCE OLIGONUCLEOTIDES IN
SYNTHETIC OLIGONUCLEOTIDE PREPARATIONS
TITLE (FRENCH): COMPOSITIONS ET PROCEDES D'IDENTIFICATION ET DE
QUANTIFICATION D'OLIGONUCLEOTIDES A SEQUENCE DE
DELETION DANS DES PREPARATIONS D'OLIGONUCLEOTIDES DE
SYNTHESE
INVENTOR(S): CHEN, Danhua;
SRIVATSA, G., Susan
PATENT ASSIGNEE(S): ISIS PHARMACEUTICALS, INC.;
CHEN, Danhua;
SRIVATSA, G., Susan
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9911820	A1	19990311

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
 GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
 BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
 BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US18084 A 19980901
 PRIORITY INFO.: US 1997-08/923,771 19970902

L4 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1998027425 PCTFULL ED 20020514
 TITLE (ENGLISH): LARGE-SCALE PURIFICATION OF FULL LENGTH
 OLIGONUCLEOTIDES BY SOLID-LIQUID AFFINITY EXTRACTION
 TITLE (FRENCH): PURIFICATION A GRANDE ECHELLE D'OLIGONUCLEOTIDES DE
 LONGUEUR TOTALE PAR EXTRACTION PAR AFFINITE
 SOLIDE-LIQUIDE
 INVENTOR(S): CHEN, Danhua;
 SRIVATSA, Githa, Susan;
 COLE, Douglas, L.
 PATENT ASSIGNEE(S): ISIS PHARMACEUTICALS, INC.;
 CHEN, Danhua;
 SRIVATSA, Githa, Susan;
 COLE, Douglas, L.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9827425	A1	19980625

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
 GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
 BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
 CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US23284 A 19971218
 PRIORITY INFO.: US 1996-8/769,951 19961219

=> d kwic 2

L4 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

=> d kwic 4

L4 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . gag 28, 29
 HIV AR 177 30
 HIV / tat, vpr, rev, 31r 32
 env, nef
 HIV / pol, env, vir 3 3 3 4
 HIV-1 / tat, rev, env, 3 5 3 6
 nef
 HIV / gp120 ISIS 5320 37
 Hepatitis C virus ISIS 6547 38
 - 68
 TABLE 6: OLIGONUCLEOTIDES DESIGNED. . .

Methylenemethylimino linked oligonucleosides, also
 identified as MMI linked oligonucleosides, methylenedi-

methylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, . . .

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.66	10.87

STN INTERNATIONAL LOGOFF AT 13:11:35 ON 29 JUN 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	6 MAY 11	KOREAPAT updates resume
NEWS	7 MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8 MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	9 MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	10 JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11 JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and

and display fields

NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
 V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:33:47 ON 29 JUN 2006

```
=> file pctfull
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
                              ENTRY          SESSION
FULL ESTIMATED COST          0.21          0.21
```

FILE 'PCTFULL' ENTERED AT 13:34:04 ON 29 JUN 2006
 COPYRIGHT (C) 2006 Univentio

```
FILE LAST UPDATED:          27 JUN 2006          <20060627/UP>
MOST RECENT UPDATE WEEK:    200625          <200625/EW>
FILE COVERS 1978 TO DATE
```

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
 SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
 (last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,
 PLEASE SEE HELP COST <<<

```
=> s WO200166689/pn
L1          1 WO200166689/PN
            (WO2001066689/PN)
```

```
=> s l1 and (growth factor)
142211 GROWTH
2617 GROWTHS
142685 GROWTH
      (GROWTH OR GROWTHS)
180880 FACTOR
189280 FACTORS
271252 FACTOR
      (FACTOR OR FACTORS)
42337 GROWTH FACTOR
```

(GROWTH(W) FACTOR)

L2 1 L1 AND (GROWTH FACTOR)

=> d kwic

L2 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN
PI WO 2001066689 A2 20010913

DETD 4,10.4 STEM CELL GROWTH FACTOR ACTIVITY

A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, . . .

It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in combination with the polypeptide of the invention to achieve the desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), . . . soluble IL-6 receptor fused to IL-6, macrophage inflammatory protein 1- α (MIP-1 α), G-CSF, GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), neural growth factors and basic fibroblast growth factor (bFGF).

... mature cells. Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct. . .

In vitro cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell

42 sources (including hematopoietic stem cells and embryonic stem cells) and. . . Acad. Sci. U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on. . .

... invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), insulin-like growth factor (IGF), as well as cytokines described herein.

... with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF),

platelet derived growth factor (PDGF), transforming growth factors (TGF-a and TGF-P), and insulin-like growth factor (IGF).

matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor 1), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.45	5.66

STN INTERNATIONAL LOGOFF AT 13:36:21 ON 29 JUN 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	4	DEC 18	CA/CAPplus patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPplus accession number crossover limit increased to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPplus enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPplus updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPplus enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields